| Report Date | |
| Manager | |
| Fund Name | |
| Strategy | |
| Latest Return Date | |
| Latest Return | |
| Latest 6 Months | |
| Latest 12 Months | |
| Latest 24 Months | |
| Annualised Since Inception | |
| Inception Date | |
| FUM (millions) | |
| Fund Overview | |
| Manager Comments | Key positive contributions came from our holdings in Sanofi, Oracle, BAT, GlaxoSmithKline and IBM, with BSkyB being the sole detractor. However, the main driver of the Fund's return in May came from the 7.7% depreciation of the Australian dollar against the US dollar. With the Fund's currency exposure 100% unhedged,the Fund benefited from the AUD's fall (and remains currency unhedged). Despite the strong absolute performance in May, the relative performance of the Fund against the equity benchmark was impacted by the rotation from defensive stocks to financial and cyclical stocks. Insync's philosophy is to invest in the more predictable growth companies and to include downside protection strategies. That has delivered positive absolute returns during previous market downturns. The Fund's average investment market cap is A$103.4bn and the weighted avg forecast dividend yield is 2.97%. |
| More Information | » View detailed profile of this fund |
